NMN and NR Before Surgery: How Long Should You Stop Taking Them?

What Are NMN and NR, and Why Are So Many Women Taking Them?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursor molecules the body converts into NAD+ (nicotinamide adenine dinucleotide), a coenzyme present in every cell and required for mitochondrial energy production, DNA repair, and sirtuin activation. NAD+ levels decline with age, and that decline is steeper and faster in women after menopause than in age-matched men, which helps explain the surge in interest among women in their 40s, 50s, and beyond.

NMN and NR are sold as dietary supplements, not prescription drugs, meaning they sit outside FDA drug approval requirements. They are not regulated for potency, purity, or safety with the same rigor applied to pharmaceuticals.

Why Women Are the Core NMN User Group

Perimenopausal and postmenopausal women represent a disproportionately large share of NAD precursor supplement users. The appeal is real: declining estrogen accelerates mitochondrial dysfunction, and NAD+ supports the same cellular repair pathways that estrogen previously up-regulated. Clinicians at WomanRx see women using NMN for energy, cognitive clarity, metabolic support, and as an adjunct to hormone therapy.

Women with PCOS also use NMN, often alongside metformin, because of overlapping interest in insulin sensitivity. Yoshino et al. (Science, 2021) is the most frequently cited trial: a 10-week randomized, placebo-controlled study in postmenopausal women with prediabetes found that oral NMN at 250 mg/day increased skeletal muscle insulin sensitivity, with improvements in insulin signaling and remodeling of muscle gene expression. This is the only published RCT to date that enrolled an exclusively female cohort for NMN efficacy.

The Supplement Labeling Gap

Because NMN and NR carry no drug label, they carry no surgeon-facing medication list prompt. Most pre-operative intake forms ask about prescription drugs and common supplements like fish oil or vitamin E, but rarely name NMN or NR explicitly. Women often do not volunteer the information because they do not think of a "wellness supplement" as something that requires disclosure. That gap is the core problem addressed in this article.

Why the Pre-Surgery Hold Window Exists

Stopping NMN and NR before surgery is not a reflex precaution applied to all supplements. There are specific pharmacological reasons the hold window matters, and each one is relevant to how women metabolize these compounds.

Platelet Function and Bleeding Risk

Nicotinamide and its downstream metabolites interact with purinergic signaling pathways. ADP-mediated platelet aggregation, the mechanism through which platelets clump at wound sites, depends in part on purine nucleotide availability. High-dose nicotinamide can mildly inhibit ADP-induced platelet aggregation in vitro, and while clinical bleeding studies with NMN specifically are absent, the mechanistic concern is present. Pharmacological reviews of nicotinamide's effects on platelet function suggest the effect is dose-dependent and additive with NSAIDs or anticoagulants that some perimenopausal women already take for joint pain or cardiovascular risk reduction.

The practical implication: if you take NMN at doses above 500 mg/day alongside ibuprofen or low-dose aspirin, your surgical team needs to know before any procedure involving significant hemostasis.

Vasodilation and Anesthetic Interaction

NMN and NR both feed into NAD+, which activates sirtuins and PARP enzymes, but NAD+ also feeds the production of NADPH, a cofactor for nitric oxide synthase. Elevated NAD+ may therefore modestly increase nitric oxide bioavailability, which translates to vasodilation. Under general or neuraxial anesthesia, vasodilation compounds the hypotensive effect of anesthetic agents. Women already tend to have lower mean arterial pressures intraoperatively than men of comparable weight, partly because of smaller vascular beds and lower baseline sympathetic vascular tone. Adding a supplement that may widen peripheral vessels introduces a risk that is easier to eliminate than to manage on the table.

Sirtuin Activation and Wound Healing: A Double-Edged Effect

Sirtuin-1 (SIRT1) activation, one of the downstream effects of elevated NAD+, generally supports tissue repair. That sounds like a reason to keep taking NMN through recovery rather than stopping it. The complication is that SIRT1 also modulates inflammatory signaling, which the body needs in a tightly regulated sequence immediately after surgery. Blunting early post-operative inflammation may theoretically slow the initial healing phase even while accelerating later repair. No human trial has tested NMN's effect on post-surgical wound healing, so the precautionary hold window before surgery covers both the bleeding risk and this unresolved mechanistic question.

The 7-Day Hold Window: Where Does It Come From?

No FDA guidance, no ACOG practice bulletin, and no American Society of Anesthesiologists (ASA) formal statement currently mandates a specific stop window for NMN or NR. The 7-day figure circulating in perioperative medicine is extrapolated from two sources.

First, the ASA's framework for dietary supplements recommends stopping most herbal and supplement products at least 7 days before elective surgery based on pharmacokinetic modeling of how long supplement effects persist after the last dose. Second, the half-life of NMN after oral ingestion is short (plasma NMN peaks within 2-3 hours and is largely cleared within 24 hours), but its downstream effect, elevated intracellular NAD+, persists longer. Intracellular NAD+ concentrations after a sustained supplementation course may take 5-7 days to return to pre-supplementation baseline after stopping the supplement. That plateau, not the plasma half-life, drives the 7-day recommendation.

What Your Surgical Team Wants to Know

When you disclose NMN or NR to your surgeon or anesthesiologist, provide these specifics:

• The daily dose in milligrams (common ranges are 250 mg, 500 mg, and 1,000 mg/day)
• How long you have been taking it continuously
• Whether you take it alongside other NAD-modulating compounds (niacin, resveratrol, pterostilbene)
• Any concurrent anticoagulants, antiplatelet drugs, or vasodilatory medications

A surgical team cannot assess risk from "I take a longevity supplement." Precise disclosure allows precise perioperative planning.

The WomanRx Perioperative Disclosure Framework for NMN/NR:

| Information to disclose | Why it matters | |---|---| | Daily NMN/NR dose (mg) | Dose-dependent platelet and vasodilatory effects | | Duration of continuous use | Longer use means higher intracellular NAD+ accumulation | | Concurrent niacin or resveratrol | Additive NAD+ pathway load | | Concurrent antiplatelet drugs | Additive bleeding risk | | Hormone therapy (estrogen/progesterone) | Estrogen modulates NAD+ metabolism; interaction unknown |

NMN, NR, and Women Across Life Stages

Reproductive Years (Ages 18-40)

Women of reproductive age using NMN typically do so for PCOS-related metabolic support or general energy. The insulin-sensitizing data from Yoshino et al. Used a postmenopausal cohort, so direct extrapolation to younger women with PCOS is not supported by trial evidence. Small pilot data suggest NAD+ precursors improve mitochondrial function in granulosa cells, which has sparked interest in fertility circles, but no human RCT has confirmed reproductive benefit of NMN in PCOS.

If you are undergoing a surgical procedure such as laparoscopy for endometriosis or ovarian cystectomy, the same 7-day hold applies. Mention NMN on your pre-op form even if your gynecologist has not specifically asked.

Trying to Conceive

Animal studies in aged mice showed NMN supplementation improved oocyte quality and reversed age-related fertility decline, findings that generated significant media coverage. The mouse data are mechanistically interesting because declining NAD+ impairs spindle assembly during meiosis, contributing to aneuploidy. Bertoldo et al. (Cell Reports, 2020) demonstrated this effect in a mouse model of age-associated infertility. No human RCT has replicated this in women trying to conceive, and ASRM has not issued guidance on NMN for fertility. The evidence gap here is significant. Anyone using NMN specifically to support fertility should discuss it with their reproductive endocrinologist before any egg retrieval or uterine procedure.

Pregnancy and Lactation

NMN and NR are not recommended during pregnancy. No adequate human safety data exist. Animal teratogenicity studies have not been conducted at doses equivalent to the 250-1,000 mg/day range used by humans. NAD+ is essential for embryonic development, and the NAD+ salvage pathway is active in the placenta, but supplementing the substrate (NMN) at pharmacological doses during organogenesis carries unknown risk. The precautionary position is to stop NMN before attempting conception and not resume it until after weaning.

Lactation transfer of NMN and NR metabolites has not been studied. Breast milk naturally contains NAD+ precursors, but whether supplemental doses increase transfer and what effect that would have on a nursing infant is entirely unknown. The FDA's Office of Women's Health guidance on dietary supplements during pregnancy advises against use of any supplement without explicit clinical indication during pregnancy or lactation.

Contraception: women of reproductive age using NMN should be aware that its safety in early pregnancy (before a pregnancy is recognized) is unknown. If you are sexually active and not trying to conceive, reliable contraception is prudent while taking any unproven supplement with active embryonic NAD+ pathway involvement.

Perimenopause (Ages 40-55, Variable)

This is where the strongest interest and the strongest mechanistic rationale converge. Estrogen loss in perimenopause reduces the expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, meaning the body becomes less efficient at making NAD+ from dietary niacin at exactly the time aging further suppresses NAD+ production. Supplementing with NMN bypasses the NAMPT step and directly provides the substrate for NAD+ synthesis.

Women in perimenopause who are also on hormone therapy (HT) face an interaction question that has not been formally studied: estrogen itself up-regulates NAMPT, so women on HT may have different baseline NAD+ status than those who are not. Whether this changes the effective dose of NMN needed for metabolic benefit is unknown.

For perimenopausal women scheduled for gynecological surgery (hysterectomy, myomectomy, pelvic floor repair), the 7-day hold window and full disclosure of both NMN and any concurrent HT are essential. Anesthetic drug metabolism, bleeding tendency, and vascular tone all differ in the perimenopausal hormonal environment.

Postmenopause

The Yoshino et al. Trial enrolled postmenopausal women and is the strongest human evidence for NMN efficacy in any female cohort. After 10 weeks of 250 mg/day NMN, participants showed significant improvement in insulin-stimulated glucose disposal and upregulation of muscle insulin signaling genes, without serious adverse events. This is the data point most women and clinicians cite when defending NMN use in this population.

Postmenopausal women also face higher surgical frequency (orthopedic, colorectal, urological, and gynecological oncology procedures). Clear perioperative protocols for this group are therefore not a theoretical concern. If you are postmenopausal and taking NMN for metabolic health, treat it as a medication on your surgical disclosure form.

Drug and Supplement Interactions Relevant to Women

NMN and NR are not pharmacologically inert. Several interactions are worth naming:

Metformin: Widely used in women with PCOS and type 2 diabetes. Metformin inhibits complex I of the mitochondrial electron transport chain and activates AMPK. NMN also activates SIRT1 and AMPK through NAD+. The combination may produce additive AMPK activation, which is likely neutral to beneficial metabolically but has not been studied in a combined human trial. A 2023 pharmacology review noted the interaction as "theoretically synergistic but clinically uncharacterized."

Hormone therapy (estrogen plus or minus progesterone): Estrogen up-regulates NAMPT, as noted above. Combined use of estrogen and NMN has not been studied. No safety signal exists, but no benefit has been confirmed over HT alone.

Warfarin or direct oral anticoagulants (DOACs): Nicotinamide derivatives can interact with CYP2C9 and CYP3A4 at high doses. Women on warfarin for atrial fibrillation or venous thromboembolism should have their INR monitored if they start or stop high-dose NMN. Stopping NMN 7 days before surgery removes this variable cleanly.

Alcohol: Alcohol metabolism competes with NAD+. Women metabolize alcohol differently than men (lower ADH activity, higher bioavailability per gram), and adding NAD+ precursors in heavy drinkers may alter alcohol clearance in ways that are not yet quantified.

What the Evidence Gap Means for Your Decision

Women have been systematically under-represented in supplement and longevity research. The Yoshino et al. Trial is notable precisely because it enrolled only women, a design choice that should be standard but is not. The majority of NMN mechanistic studies used male rodents or mixed-sex human cohorts where sex-stratified results were not reported.

This means several things practically:

• Dosing recommendations for women are extrapolated from male or mixed data.
• The platelet, vascular, and anesthetic interaction risks described above are biologically plausible but not confirmed in women-specific perioperative trials.
• The precautionary 7-day hold is reasonable exactly because the data gap means we cannot confidently say the risk is zero.

Honest clinical communication requires saying that directly rather than presenting the hold window as settled science.

Resuming NMN After Surgery

No specific guidance exists for the post-operative restart window. General perioperative supplement practice suggests waiting until:

1. Oral intake is fully resumed and tolerated
2. Any surgical drains or wound packs have been removed
3. Post-operative anticoagulation, if prescribed, is stable

In practice this means most women can consider restarting NMN 7-14 days after an uncomplicated procedure, with their surgeon's clearance. Women recovering from major abdominal or pelvic surgery, where inflammatory signaling is critical to healing for 4-6 weeks, may want to wait the full 6-week post-operative window before resuming.

There is no evidence that stopping NMN briefly causes rebound harm. NAD+ levels decline slowly after cessation, and a 2-3 week interruption in a healthy supplement user produces no documented adverse effect.

Who This Is Right For and Who Should Not Take NMN Perioperatively

Likely Appropriate Candidates (outside of surgery windows)

• Postmenopausal women with prediabetes or metabolic syndrome seeking insulin sensitivity support, where the Yoshino et al. Data applies most directly
• Perimenopausal women with significant fatigue or cognitive symptoms who have not responded adequately to lifestyle changes alone
• Women with PCOS using NMN as a metabolic adjunct alongside evidence-based treatments (metformin, lifestyle modification, combined oral contraceptives where indicated)

Who Should Be Most Cautious

• Women scheduled for any elective surgery within 7 days
• Women who are pregnant, trying to conceive, or breastfeeding
• Women on anticoagulants or antiplatelet therapy without their prescribing physician's knowledge of NMN use
• Women with known bleeding disorders (von Willebrand disease affects approximately 1 in 100 women and is often under-diagnosed)
• Women on warfarin with unstable INR